Reumatologia clinica最新文献

{"title":"Investigating potential biomarkers and therapeutic targets for patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) through the utilization of cytokine profiling","authors":"Akhil Akhil ,&nbsp;Rohit Bansal ,&nbsp;Jyotsana Kaushal ,&nbsp;Aman Sharma ,&nbsp;Archana Bhatnagar","doi":"10.1016/j.reumae.2025.101805","DOIUrl":"10.1016/j.reumae.2025.101805","url":null,"abstract":"<div><h3>Objectives</h3><div>Examining cytokine profile complexities in chronic autoimmune disorders holds significant clinical importance. In order to address the similarities and differences related to SLE and RA, it was necessary to evaluate their cytokine chemokine profiles. Such analyses would give pointers towards differences, leading thereby to explore the potential of cytokines/chemokines as biomarkers. The study was therefore driven by the concept of understanding the major differences at this level with a hope of contribution towards diagnostics/theranostics. A multiplex study was carried out on systemic autoimmune disorders, such as SLE and RA, analysing forty analytes in comparison with healthy controls.</div></div><div><h3>Methodology</h3><div>Age and sex matched healthy donors and patients (<em>n</em> <!-->=<!--> <!-->38) were recruited and plasma cytokine profiling was done by Bio-plex multiplex immunoassay system.</div></div><div><h3>Results</h3><div>A comparison with healthy volunteers revealed differential alteration in various chemokines in SLE and RA, respectively. Protein interaction analysis identified a core complex of chemokines (CXCL10, CCL5, CXCL12, CXCL9, CXCL1, and CXCL27) as central modulators, suggesting their potential as biomarkers. Drug prediction using the DSigDB database identified acetovanillone as a potential drug against this core complex. In comparing lupus patients with or without arthritis comorbidity, elevated levels of cytokines: IL-12, SCF, and TNF-a were prominently associated with arthritis in SLE. TNF-a emerged as a potential indicator specifically for arthritis.</div></div><div><h3>Conclusion</h3><div>This study enhances our understanding of the complex interplay of cytokine/chemokine in these systemic conditions and suggests their utility as targets and diagnostic paradigms for detection.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 1","pages":"Article 101805"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nailfold capillaroscopic changes in patients with glomerular diseases","authors":"Hend Adel ,&nbsp;Ahmed A. Eldeeb ,&nbsp;Fatma Hamdy","doi":"10.1016/j.reumae.2025.101803","DOIUrl":"10.1016/j.reumae.2025.101803","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Glomerulonephritis is a heterogenous group of diseases which is diagnosed mainly by renal biopsy. This study aims to assess nailfold capillaroscopic changes in patients with glomerular diseases.</div></div><div><h3>Patients and methods</h3><div>This study was conducted on 50 patients with glomerular disease confirmed by renal biopsy and 50 age and sex matched healthy controls. Clinical, laboratory evaluation and nailfold capillaroscopic examination were done for all participants.</div></div><div><h3>Results</h3><div>Lupus nephritis was the most common pathological type among glomerulonephritis group [17 (34%)], followed by focal segmental glomerulosclerosis [9 (18%)]. Tortuous capillaries were significantly higher in patients with primary glomerular diseases compared to healthy persons (92.9% vs 58%, <em>P</em> <!-->&lt;<!--> <!-->0.001). The diameter was significantly lower in patients with primary glomerular diseases compared to healthy control group (15.6<!--> <!-->μm vs 18.9<!--> <!-->μm, <em>P</em> <!-->=<!--> <!-->0.001). Subpapillary venous plexus (28.6% vs 6%, <em>P</em> <!-->=<!--> <!-->0.02) and capillary microhemorrhage (32% vs 0%, <em>P</em> <!-->&lt;<!--> <!-->0.001) were significantly more frequent in patients with primary glomerular diseases compared to the control group. Patients with lupus nephritis had higher capillary diameter (19.5 vs 15.6<!--> <!-->μm, <em>P</em> <!-->=<!--> <!-->0.02), width (55.6 vs 44<!--> <!-->μm, <em>P</em> <!-->=<!--> <!-->0.003) and microhemorrhage (64.7% vs 32%, <em>P</em> <!-->=<!--> <!-->0.03) compared to patients with primary glomerulonephritis. There was a statistically significant difference as regard diameter (<em>P</em> <!-->=<!--> <!-->0.005) and length (<em>P</em> <!-->=<!--> <!-->0.02) between different classes of lupus nephritis.</div></div><div><h3>Conclusion</h3><div>More tortious capillaries and lower capillary diameter were found in patients with primary glomerular disease compared to healthy persons. Lupus nephritis patients had more dilated capillaries and more capillary microhemorrhage compared to primary glomerulonephritis patients.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 1","pages":"Article 101803"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autologous stem cell transplantation in systemic sclerosis: 4 cases","authors":"Marta de la Rubia Navarro,&nbsp;Samuel Leal Rodríguez,&nbsp;José Andrés Román Ivorra","doi":"10.1016/j.reumae.2025.501810","DOIUrl":"10.1016/j.reumae.2025.501810","url":null,"abstract":"<div><h3>Objective</h3><div>The aim is to describe clinical and serological features, previous and current therapies, and adverse events in four systemic sclerosis patients (SSc) who undergo autologous hematopoietic stem cells transplantation (AHSCT).</div></div><div><h3>Methods</h3><div>Descriptive, cross-sectional study including SSc patients according ACR/EULAR 2013 criteria. Clinical and serological data, data related to current and previous therapy and adverse events were collected from 2014 to 2023.</div></div><div><h3>Results</h3><div>Four female patients were included, with a mean age of 49 (6.78) years old and a mean of 32.5 (7) months since diagnosis to AHSCT. Mean mRodnan score (mRSS) was 33.75. All cases underwent a skin improvement measured by mRSS (mean difference of 14.75) and lung function (DLCO) remained stable. Only one patient presented a pneumonia post-AHSCT, that required admission to intensive care unit, with improvement and complete resolution of infection a few days after admission.</div></div><div><h3>Conclusions</h3><div>AHSCT is an appropriate therapeutic option in rapidly progressive diffuse SSc patients, with a good safety profile in our cohort.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 1","pages":"Article 501810"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143043985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of liraglutide among patients with psoriatic arthritis and obesity","authors":"Joana Nicolau ,&nbsp;Antoni Nadal ,&nbsp;Inmaculada Ros ,&nbsp;Lluís Masmiquel","doi":"10.1016/j.reumae.2025.501809","DOIUrl":"10.1016/j.reumae.2025.501809","url":null,"abstract":"","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 1","pages":"Article 501809"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143043988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mepolizumab efficacy and safety in patients with eosinophilic granulomatosis with polyangiitis in real practice: Data from a Spanish retrospective multicentric register from Rheumatology departments","authors":"Francisco Rubiño Juárez ,&nbsp;Rosario García de Vicuña ,&nbsp;Esther Vicente ,&nbsp;Esther Rodríguez Almaraz ,&nbsp;Nuria Lozano Rivas ,&nbsp;Mercedes Freire González ,&nbsp;Alejandro Olivé Marqués ,&nbsp;Annika Nack ,&nbsp;Javier Narváez García ,&nbsp;Patricia Moya Alvarado ,&nbsp;Esther Uriarte Itzazelaia ,&nbsp;Nerea Alcorta Lorenzo ,&nbsp;José Luis Marenco de la Fuente ,&nbsp;Consuelo Ramos ,&nbsp;Valvanera Pinillos Aransay ,&nbsp;Ricardo Blanco Alonso ,&nbsp;Fabricio Benavides Villanueva ,&nbsp;María Paz Martínez Vidal ,&nbsp;Jesús María González Martín ,&nbsp;Íñigo Rúa-Figueroa","doi":"10.1016/j.reumae.2025.101806","DOIUrl":"10.1016/j.reumae.2025.101806","url":null,"abstract":"<div><h3>Objectives</h3><div>Eosinophilic granulomatosis with polyangiitis (EGPA) is a type of ANCA-associated vasculitis mostly mediated by eosinophils. Mepolizumab (MPZ) reduces the absolute number of eosinophils in the peripheral blood and tissues and has proven efficacy in the maintenance of EGPA, as shown in a randomized controlled trial. The aim of this study is to describe the use of MPZ in EGPA in real clinical practice.</div></div><div><h3>Methods</h3><div>This is a descriptive, retrospective and comparative analysis of the clinical features, course, response rates, outcomes and adverse effects of patients receiving MPZ for EGPA in thirteen Spanish Rheumatology departments.</div></div><div><h3>Results</h3><div>A total of 30 EGPA patients treated with MPZ were included in the analysis. Up to 19 patients needed at least one concomitant immunosuppressant. The mean follow-up was 16 months. The use of MPZ reduced the median Birmingham Vasculitis Activity Score (BVAS), as well as the mean C-reactive protein and the levels of eosinophils. In addition, the median dose of glucocorticoids (GC) required was reduced in 79.3% of the patients and was completely suspended in 57.1%. Interestingly, the median Vasculitis Damage Index (VDI) was also calculated in 27 patients (90%), and remained stable (3 [0–12] pre-MPZ and 3 [0–12] post-MPZ). None of the patients suffered severe adverse effect, local reactions or serious infections during the treatment.</div></div><div><h3>Conclusions</h3><div>Our data on the real practice use of MPZ in EGPA suggests that this drug has good efficacy, is safe and reduces the dependence on glucocorticoids or even their complete withdrawal. Furthermore, it appears to prevent the organic damage progression associated with this disease.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 1","pages":"Article 101806"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular risk in patients with osteoporosis within a Rheumatology setting. Results from a Spanish survey-based multicenter study","authors":"Enrique Casado ,&nbsp;Irene Gómez-Olmedo ,&nbsp;on behalf of the VASOS Study Group","doi":"10.1016/j.reumae.2025.101799","DOIUrl":"10.1016/j.reumae.2025.101799","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Osteoporosis (OP) and cardiovascular diseases (CVDs) share pathophysiological mechanisms and risk factors. The severity of OP correlates with cardiovascular (CV) risk, suggesting the need for integrated clinical approaches. The VASOS study aimed to have an approach to the frequency of comorbidities, especially CVD, and cardiovascular risk factors (CVRF), in OP patients in Spain within a Rheumatology setting, assessing their possible impact on OP treatment decisions.</div></div><div><h3>Materials and methods</h3><div>Spanish survey-based multicentre study involving 62 Spanish rheumatologists, which give information from the last 10 patients. Participants were selected according to their clinical expertise and their geographical area. Questions were oriented to describe the profile of patients (OP and CVRF), and prescription habits. “Influence on treatment choice” was only accounted if the presence of one or more CVRF could affect the selection of the OP treatment.</div></div><div><h3>Results</h3><div>Data from 620 patients were collected. The patients were predominantly women (85.2%) with primary OP (73.2%). Bisphosphonates, denosumab and teriparatide were the most used treatments. Most common comorbidities included inflammatory rheumatic or autoimmune diseases, endocrinopathies and major CVD. CVRF influenced treatment choice for 82.3% of rheumatologists, who often avoided prescribing romosozumab, selective oestrogen receptor modulators (SERMs), and menopausal hormone therapy (MHT).</div></div><div><h3>Conclusions</h3><div>Most patients with OP are women with primary OP, often having CVRF. Oral bisphosphonates, denosumab, and teriparatide are the preferred treatments, avoiding MHT, SERMs, and romosozumab in patients with CVRF.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 1","pages":"Article 101799"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bibliometric analysis of the scientific production of rheumatology departments in Spain during the 2013-2022 period","authors":"Daniel Seoane-Mato ,&nbsp;Fernando Sánchez-Alonso ,&nbsp;Mercedes Guerra-Rodríguez ,&nbsp;Enrique González-Dávila ,&nbsp;Federico Díaz-González","doi":"10.1016/j.reumae.2025.101807","DOIUrl":"10.1016/j.reumae.2025.101807","url":null,"abstract":"<div><h3>Background and objective</h3><div>Bibliometric studies of scientific production in Spanish Rheumatology are scarce. The aim of this study was to analyze the bibliographic production of Rheumatology Services in Spain over the period 2013-2022.</div></div><div><h3>Materials and methods</h3><div>Original articles and reviews with the affiliation of the first or corresponding author to a Spanish rheumatology Service/Department/Section/Unit were identified in the Web of Science Core Collection and Scopus databases. Keywords and titles were used to classify articles by field (clinical, epidemiological or basic) and pathology. International collaborations and collaborations between Autonomous Communities (AC) were identified. Quantitative bibliometric indicators were obtained (number of articles published per year, pathology and AC) and impact indicators were obtained (based on the number of citations per article). The H-index was also calculated.</div></div><div><h3>Results</h3><div>The total number of publications was 2321, with an annual growth rate of 4.1% in the period analyzed. In 14.1% of the articles there were international collaborations, mainly with the United States and the United Kingdom, while between ACs the most numerous were between Madrid and Catalonia. The pathologies with the highest H-index were rheumatoid arthritis (RA), spondyloarthropathies (SpA), osteoarthritis and vasculitis (34, 32, 28 and 26, respectively). The H-index for the Spanish rheumatology services as a whole was 69.</div></div><div><h3>Discussion and conclusions</h3><div>The scientific production of rheumatology services/departments/sections/units in our country increased between 2013 and 2022. By pathology, the scientific production in RA and SpA stands out.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 1","pages":"Article 101807"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143043987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating different perspectives to define a concept of comprehensive remission in rheumatoid arthritis: The SUMAR project","authors":"Alejandro Balsa ,&nbsp;José Luis Andreu ,&nbsp;Juan Carlos Hermosa-Hernán ,&nbsp;Josefa León-Navarro ,&nbsp;Jordi Nicolas Pico ,&nbsp;José Javier Pérez Venegas ,&nbsp;Susana Romero-Yuste ,&nbsp;Raimon Sanmarti ,&nbsp;Antonio Ignacio Torralba Gómez-Portillo ,&nbsp;Juan Carlos Valenzuela-Gámez ,&nbsp;Jordi Cohen","doi":"10.1016/j.reumae.2025.101800","DOIUrl":"10.1016/j.reumae.2025.101800","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>The SUMAR project aimed to establish a consensus on the concept of remission in patients with rheumatoid arthritis (RA) that takes into account the different perspectives of patients, health care professionals and health care managers.</div></div><div><h3>Materials and methods</h3><div>The scientific committee comprised a rheumatologist who acted as a national coordinator, 4 rheumatologists, 1 primary care physician, 1 nurse, 2 hospital pharmacists, 2 health care managers and 1 member of a patient advocacy group. The study was undertaken from 2020 to 2021 in three phases: (1) analysis of several perspectives on remission in RA with the participation of 275 patients, 160 rheumatologists and 31 health care managers; (2) an integrative definition of remission, which included two multidisciplinary workshops with 11 and 12 participants; and (3) extension and dissemination with up to 200 participants in 7 regional multidisciplinary meetings.</div></div><div><h3>Results</h3><div>The concept of remission in the different settings and by the different stakeholders was heterogeneous. It was agreed that, in addition to inflammatory activity, remission should include pain and functionality as well as the duration of remission. For the participants, the definition of remission varied depending on the clinical scenario, without or with structural damage, seeking to “normalize” the outcomes in the former and avoid progression in the latter. The implementation of the concept of comprehensive remission was considered less feasible, and the main barriers to implementation were the lack of time for consultation and the variability in information technology systems across the different autonomous communities.</div></div><div><h3>Discussion and conclusions</h3><div>This definition of remission is not only based on the concept of the presence or absence of inflammatory activity based on existing indexes, but also includes variables directly reported by the patient that are related to their health and quality of life.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 1","pages":"Article 101800"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Connecting the dots: Bilateral thigh pain, dental anomaly, recurrent pregnancy loss to a complex diagnostic journey","authors":"Sabarinath Mahadevan,&nbsp;Ishwarya Ramadoss,&nbsp;P.S. Arul Raja Murugan","doi":"10.1016/j.reumae.2025.101804","DOIUrl":"10.1016/j.reumae.2025.101804","url":null,"abstract":"","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 1","pages":"Article 101804"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do patients with axial spondyloarthritis with active disease suffer from greater disease burden and work impairment? Results from the International Map of Axial Spondyloarthritis (IMAS)","authors":"Marco Garrido-Cumbrera ,&nbsp;Denis Poddubnyy ,&nbsp;Fernando Sommerfleck ,&nbsp;Christine Bundy ,&nbsp;Souzi Makri ,&nbsp;José Correa-Fernández ,&nbsp;Shashank Akerkar ,&nbsp;Jo Lowe ,&nbsp;Elie Karam ,&nbsp;Victoria Navarro-Compán","doi":"10.1016/j.reumae.2024.11.009","DOIUrl":"10.1016/j.reumae.2024.11.009","url":null,"abstract":"<div><h3>Background</h3><div>To assess the prevalence of clinically active disease in axial spondyloarthritis (axSpA) and its associated factors in a large global sample of patients from the International Map of Axial Spondyloarthritis (IMAS) study.</div></div><div><h3>Methods</h3><div>IMAS is a cross-sectional online survey (2017–2022) of 5557 axSpA patients. Patients were divided between those with active disease (BASDAI ≥4) and without active disease (BASDAI &lt;4). The factors evaluated were sociodemographic, lifestyle, patient-reported outcomes, employment, disease characteristics, extra-musculoskeletal manifestations, and treatment. Logistic regression analysis stratified by gender were used to evaluate the relationship between investigated factors and active disease.</div></div><div><h3>Results</h3><div>In the present study, 5295 patients who had responded to the BASDAI scale were included in the present study: 3231 were from Europe, 770 from North America, 600 from Asia, 548 from Latin America, and 146 from Africa. The mean age was 43.8<!--> <!-->±<!--> <!-->12.9 years and 55.4% were females. Patients reported a mean BASDAI of 5.4 (±2.1) with 75% having active disease (BASDAI ≥4). In South Africa, 87.0% of patients reported having active disease, compared to 68.5% in Asia. Multivariable logistic regression showed an association of active disease with higher functional limitation, greater spinal stiffness, difficulty finding a job due to axSpA and worse mental health in both genders. For males, younger age and shorter diagnostic delay, and for females, no physical activity and presence of inflammatory bowel disease were associated with active disease.</div></div><div><h3>Conclusions</h3><div>Three quarters of patients with axSpA reported clinically active disease, with higher proportion of patients with active disease in South Africa and lower proportion in Asia. Our results underline the complexity of the clinical disease activity concept in axSpA and the need for a holistic approach in the patient management, care and treatment.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 10","pages":"Pages 547-554"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}